SS
CTXR icon

SBI Securities’s Citius Pharmaceuticals CTXR Stock Holding History

SBI Securities’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.87K Buy
6,519
+2,501
+62% +$2.02K ﹤0.01% 1966
2025
Q4 		$3.12K Sell
4,018
-2
-0% -$3 ﹤0.01% 2220
2025
Q3 		$4.99K Buy
4,020
+2
+0% +$3 ﹤0.01% 2046
2025
Q2 		$6.39K Buy
4,018
+1,750
+77% +$1.6K ﹤0.01% 1875
2025
Q1 		$3.38K Sell
2,268
-14
-0.6% -$34 ﹤0.01% 2063
2024
Q4 		$9.13K Buy
+2,282
New +$15.4K ﹤0.01% 1684

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

SBI Securities's CTXR Position: Q1 2026 in Review

SBI Securities increased its Citius Pharmaceuticals (CTXR) stake by 62% in Q1 2026, buying an estimated $2.02K and bringing the position to 6,519 shares worth $5.87K. The position accounts for ﹤0.01% of the portfolio, ranked #1966.

SBI Securities first reported a position in CTXR in Q4 2024 and has held it in 6 quarters since. The position peaked at $9.13K in Q4 2024. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • SBI Securities held 6,519 shares of Citius Pharmaceuticals worth $5.87K as of Q1 2026.
  • SBI Securities bought 2,501 Citius Pharmaceuticals shares in Q1 2026, an estimated $2.02K.
  • Citius Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #1966 holding.
  • SBI Securities first reported a position in Citius Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's Citius Pharmaceuticals position peaked at $9.13K in Q4 2024.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.